Company news

Avacta Group PLC news in 2023

Avacta Group PLC's news releases, calls and decks from 2023, newest first.

View company

Appointment of Chief Business Officer

December 19, 2023

ALS-6000-101 Phase 1a Study Data

December 13, 2023

Shareholder update to review AVA6000 Phase 1a data

December 4, 2023

Avacta to present at AACR-NCI-EORTC conference

October 5, 2023

Director/PDMR Shareholding

September 29, 2023

Interim Results for the Period Ending 30 June 2023

September 28, 2023

Peel Hunt Appointed as Joint Broker

September 20, 2023

Appointment Dr.Christina Coughlin as a consultant

September 20, 2023

Successful Completion of Sixth Dose Escalation

September 19, 2023

Result of Annual General Meeting

June 28, 2023

Annual General Meeting and Shareholder Event

June 28, 2023

Completion of Fifth Dose Escalation in AVA6000

June 21, 2023

Director Appointment

June 19, 2023

Statement regarding market speculation

June 19, 2023

AGM and Shareholder Event Detailed Agenda

June 8, 2023

Second Milestone in AffyXell Joint Venture

June 5, 2023

Avacta acquires Coris Bioconcept

June 1, 2023

First Patient Dosed in the US in AVA6000 Phase 1

April 27, 2023

Preliminary Results

April 25, 2023

AVA3996 data poster presented at AACR

April 17, 2023

1st US Clinical Investigator AVA6000 Sites Opened

April 6, 2023

First Patient Dosed in Fifth Cohort of AVA6000

April 5, 2023

Notice of Results and Investor Presentation

April 3, 2023

AVA3996 data poster presentation at AACR

March 27, 2023

Statement re: Silicon Valley Bank

March 13, 2023

Avacta Therapeutics Division Science Day

February 23, 2023

Second Price Monitoring Extn

January 17, 2023

Price Monitoring Extension

January 17, 2023

Successful Completion of Fourth Dose Escalation

January 17, 2023

Calls in 2023

Decks in 2023